Liver Diseases Therapeutics Market Report 2026

The liver diseases therapeutics market size has grown strongly in recent years. It will grow from $15.18 billion in 2025 to $16.66 billion in 2026 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to high prevalence of viral hepatitis infections, increasing alcohol-induced liver disease cases, early reliance on antiviral and supportive therapies, limited treatment options for chronic liver conditions, growing hospital-based liver care.

The liver diseases therapeutics market size is expected to see strong growth in the next few years. It will grow to $24.27 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to rising burden of metabolic liver diseases, increasing adoption of immunosuppressive and targeted therapies, expanding liver cancer treatment pipelines, growing awareness of early treatment benefits, higher healthcare spending on chronic liver diseases. Major trends in the forecast period include rising demand for antiviral therapies in hepatitis treatment, growing focus on nafld and nash management, increasing adoption of immunotherapy in liver cancer, expansion of combination drug therapies, rising emphasis on long-term disease management.

The increasing prevalence of liver diseases is expected to drive the growth of the liver disease therapeutics market in the coming years. Liver disease refers to any condition that affects the liver. Liver disease therapeutics assist in managing and treating liver diseases through various interventions. For example, in December 2024, the Office for Health Improvement and Disparities, a UK government department, reported that in 2023, the number of premature deaths due to alcoholic liver disease rose by 3.6%, reaching 5,984, up from 5,776 in 2022. Consequently, the rising prevalence of liver diseases contributes to the growth of the liver disease therapeutics market.

Major companies operating in the liver disease therapeutics market are emphasizing innovative technologies, such as artificial intelligence, to assist clinicians in identifying patients with liver fibrosis early in their disease progression. Artificial intelligence in liver disease therapeutics involves the use of advanced computational algorithms and machine learning techniques to analyze medical data, supporting early detection, diagnosis, and personalized treatment approaches for liver diseases. For example, in February 2023, Predictive Health Intelligence, a UK-based healthcare information management company, introduced hepatoSIGHT. hepatoSIGHT is an AI-powered tool capable of predicting liver fibrosis in patients with chronic liver disease. It serves as a case-finding and cohort mapping tool designed to detect patients at risk of chronic liver disease (CLD). The system is secure, intuitive, and easy to use, capable of reviewing millions of lines of data within seconds to identify patients who meet specified criteria. Additionally, it offers features such as comprehensive data analysis, machine learning algorithms, real-time risk stratification, and a user-friendly interface.

In September 2025, Bausch Health Companies Inc., a Canada-based pharmaceutical and healthcare company, acquired DURECT Corporation for an undisclosed amount. Through this acquisition, Bausch Health aimed to enhance and accelerate its hepatology pipeline by incorporating an advanced-stage therapy for alcohol-associated hepatitis and expanding its late-stage liver disease R&D capabilities. DURECT Corporation is a US-based late-stage biopharmaceutical company that focuses on developing epigenetic therapies targeting dysregulated DNA methylation, with its lead asset larsucosterol in clinical development for alcohol-associated hepatitis.

Major companies operating in the liver diseases therapeutics market are Astellas Pharma Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, GlaxoSmithKline PLC, Abbott Laboratories Inc., Pfizer Inc., Sanofi SA, Johnson & Johnson Services Inc., Bayer AG, AbbVie Inc., Takeda Pharmaceutical Company Limited, AstraZeneca PLC, Gilead Sciences Inc., Alnylam Pharmaceuticals Inc., Intercept Pharmaceuticals Inc., Conatus Pharmaceuticals Inc., CymaBay Therapeutics Inc., Viking Therapeutics Inc., Madrigal Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Enanta Pharmaceuticals Inc.

North America was the largest region in the liver diseases therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the liver diseases therapeutics market report during the forecast period. The regions covered in the liver diseases therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the liver diseases therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the liver diseases therapeutics market by increasing costs associated with imported active pharmaceutical ingredients, biologics, and specialty drugs used in liver disease treatment. These impacts are more pronounced across antiviral and immunotherapy segments, particularly in regions such as asia-pacific and europe that depend on global pharmaceutical supply chains. Hospitals and ambulatory surgery centers face higher treatment and procurement costs due to tariff pressures. However, tariffs have also encouraged domestic drug manufacturing, expansion of generic therapies, and diversification of supply chains, supporting long-term market resilience.

The liver diseases therapeutics market research report is one of a series of new reports that provides liver diseases therapeutics market statistics, including liver diseases therapeutics industry global market size, regional shares, competitors with a liver diseases therapeutics market share, detailed liver diseases therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the liver diseases therapeutics industry. This liver diseases therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Liver disease therapeutics involves the treatment of various liver conditions, including those caused by viruses such as hepatitis A, B, and C. These therapeutics play a crucial role in improving the quality of life for individuals affected by liver disorders and reducing the overall burden of liver disease on healthcare systems.

The main types of liver disease therapeutics target hepatitis, non-alcoholic fatty liver disease, alcohol-induced liver conditions, and liver cancer. Hepatitis is an inflammation of the liver caused by a range of infectious viruses and noninfectious factors, leading to various health complications, some of which may be fatal. Treatments include antivirals, vaccines, chemotherapy, immunosuppressive agents, and corticosteroids. End-users comprise hospitals, ambulatory surgery centers, and other healthcare facilities.

The liver diseases therapeutics market includes revenues earned by entities by diagnosis such as imaging, laboratory tests, endoscopy, and biopsy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.